Author:

Keywords:

Peroxisomes, Catalase, Prostate cancer cell lines, Enzalutamide, G091819N#54969808, 1213623N#57061610, C14/18/088#54689605, C14/19/100#55221892

Abstract:

Prostate cancer (PCa) is the second most frequent type of cancer globally and the fifth leading cause of cancer-related mortality among men. A steadily increasing number of reports establish a strong connection between PCa and alterations in cellular redox metabolism. Here, our focus centers on elucidating how changes in peroxisomal redox metabolism intricately contribute to the biology of PCa cells. We have obtained evidence that (i) non-malignant and malignant prostate cells exhibit different redox profiles at the subcellular level, (ii) the peroxisome-associated pool of catalase is significantly higher in LNCaP and PC3 cells than in non-malignant RWPE-1 prostate cells, (iii) data obtained with commonly used PCa cell lines do not always mimic the patient’s situation, (iv) androgen receptor activation decreases catalase expression in LNCaP cells, and (v) catalase knockdown increases LNCaP cell proliferation and impedes the action of enzalutamide, a second-generation antiandrogen. We will discuss the implications of these findings.